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Human Thymic Stromal Lymphopoietin Preferentially
Stimulates Myeloid Cells1
Pedro A. Reche, Vassili Soumelis, Daniel M. Gorman, Teresa Clifford, Man-ru Liu,
Marilyn Travis, Sandra M. Zurawski, Jim Johnston, Yong-Jun Liu, Hergen Spits,
Rene de Waal Malefyt, Robert A. Kastelein,2 and J. Fernando Bazan
The sequence of a novel hemopoietic cytokine was discovered in a computational screen of genomic databases, and its homology
to mouse thymic stromal lymphopoietin (TSLP) suggests that it is the human orthologue. Human TSLP is proposed to signal
through a heterodimeric receptor complex that consists of a new member of the hemopoietin family termed human TSLP receptor
and the IL-7R a-chain. Cells transfected with both receptor subunits proliferated in response to purified, recombinant human
TSLP, with induced phosphorylation of Stat3 and Stat5. Human TSLPR and IL-7Ra are principally coexpressed on monocytes
and dendritic cell populations and to a much lesser extent on various lymphoid cells. In accord, we find that human TSLP functions
mainly on myeloid cells; it induces the release of T cell-attracting chemokines from monocytes and, in particular, enhances the
maturation of CD11c1 dendritic cells, as evidenced by the strong induction of the costimulatory molecules CD40 and CD80 and
the enhanced capacity to elicit proliferation of naive T cells. The Journal of Immunology, 2001, 167: 336–343.
T he development of functional B and T lymphocytes fromtheir immature precursor cells is in part coordinated by anetwork of soluble and membrane-bound factors. Among
these, thymic stromal lymphopoietin (TSLP)3 was first identified
as an activity from the conditioned medium of a mouse thymic
stromal line (1) that supported the development of B cells. The
activities of mouse TSLP (mTSLP) overlap with those of IL-7;
both stimulate thymocytes and mature T cells and facilitate B lym-
phopoiesis in cultures of fetal liver and bone marrow lymphocyte
precursors (2, 3). Mouse TSLP promotes the development of B
cells to the B2201/IgM1 stage, whereas IL-7 supports the devel-
opment of B cells to the less mature B2201/IgM2 pre-B cell stage
(3). The recent cloning of mTSLP cDNA revealed that the encoded
protein is a member of the hemopoietic cytokine family (4–6).
As is frequently observed among structurally related members
of the hemopoietic cytokine family, mTSLP and mIL-7 share a
receptor subunit, the IL-7R a-chain, in their respective signaling
complexes, partly explaining the overlapping biological profiles of
these two related cytokines (7). However, whereas the IL-7R com-
plex requires the common g-chain (Rgc) in addition to IL-7Ra,
mTSLP instead recruits a TSLP-specific chain named TSLPR (7,
8) that had been previously identified as an orphan hemopoietic
receptor most closely related to Rgc (9, 10). Mouse TSLP sequen-
tially binds first with low affinity to TSLPR and then forms a high
affinity complex with IL-7Ra (7). Both TSLP and IL-7 induce
tyrosine phosphorylation of the transcription factor Stat5, but
whereas IL-7-mediated signaling occurs via activation of Janus
kinases JAK1 and JAK3, TSLP is unable to activate either enzyme
(3, 11), but may instead interact with JAK2 (10). This evidence
points to as yet undefined biological effects of TSLP that are not
shared with IL-7. Although mouse TSLP was first reported in
1994, no human homologue of TSLP has been identified.
Here we describe a new human hemopoietic cytokine and its
corresponding primary receptor, respectively called hTSLP and
hTSLPR. We provide evidence that the functional receptor for
hTSLP consists of hTSLPR and hIL-7Ra, and activation of this
complex leads to phosphorylation of both Stat5 and Stat3. Biolog-
ical characterization indicates that hTSLP acts primarily on my-
eloid cells. As suggested by the coexpression profile of TSLPR and
IL-7Ra on monocytes and dendritic cells, we find that human
TSLP can induce the release of T cell-attracting chemokines from
monocytes and potently enhances the T cell stimulatory capacity
of the CD11c1 subset of dendritic cells.
Materials and Methods
Cell lines
Human 293T epithelial cells were maintained in DMEM (Life Technolo-
gies, Gaithersburg, MD) supplemented with 10% FCS. The pro-B cell line
Ba/F3 was maintained in RPMI 1640 (Life Technologies) supplemented
with 10% FCS and 10 ng/ml mouse IL-3. QBI-293A human embryonic
kidney cells used for adenovirus expression were grown in CMF-1 medium
(CellWorks, San Diego, CA). BOSC23 cells were maintained in DMEM-
10% FCS and guanine phosphoribosyltransferase selection reagents (Spe-
cialty Media, Lavellette, NJ). The cells were transferred to DMEM-10%
FCS without guanine phosphoribosyltransferase selection reagents 2 days
before transfection.
Adenovirus expression of human TSLP and purification of the
recombinant protein
The mature coding region of human TSLP (residues 29–159) was fused to
the signal sequence of mouse SLAM (12) and inserted into a modified
version of transfer vector pQB1-AdCMV5-GFP (Quantum Biotechnolo-
gies) by PCR. Recombinant adenovirus was produced as described in
Quantum applications manual 24AL98. Recombinant virus was used to
infect 5 3 108 cells in 1 l CMF-1 with culture in a Nunc Cell Factory
(Nalge Nunc, Naperville, IL) for 3 days. The culture medium was clarified
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by centrifugation, dialyzed, and filtered before application to a 5-ml Q-
Sepharose column. The Q-Sepharose flow-through, which contained hu-
man TSLP, was loaded onto a 5-ml HiTrap heparin (Pharmacia, Uppsala,
Sweden) column at 5 ml/min. The column was washed with 50 mM Tris-
HCl (pH 8.0) and 1 mM EDTA and eluted with a gradient from 0 to 2.5 M
NaCl in 50 mM Tris-HCl (pH 8.0) and 1 mM EDTA. The peak fractions
were concentrated, dialyzed against PBS and quantitated by SDS-PAGE
and Coomassie staining using lysozyme as a standard. A similar procedure
was followed to prepare mouse TSLP.
Ba/F3 retroviral-mediated gene transfer and proliferation assays
Human IL-7Ra cDNA and human TSLPR cDNA were cloned by PCR in
the retroviral vectors pMX and its derivative pMX-puro to give pMX-hIL-
7Ra and pMX-puro-TSLPR, respectively (13). The BOSC23 packaging
cell line was transiently transfected with retrovirus constructs using Fugene
6 (Life Technologies) according to the manufacturer’s protocol. Retrovi-
rus-containing supernatants were collected after 2 days. Ba/F3 cells were
infected with retroviral supernatants for 48 h on petri dishes coated with 40
mg/ml recombinant fibronectin fragments (Retronectin; Takara, Shiga, Ja-
pan). After 48 h puromycin (1 mg/ml) was added to those cells infected
with virus obtained from pMX-puro constructs. The efficiency of infection
of Ba/F3 cells was .90% as assessed by parallel infection with the test
construct pMXI-EGFP encoding the enhanced green-fluorescent protein
(EGFP). Proliferation assays using Ba/F3 cells were performed as previ-
ously described (14). Cells were washed three times with RPMI medium
and plated at a density of 5000 cells/well. Cells were grown with serial
3-fold dilutions of mouse IL-3, human and mouse TSLP, or human IL-7
(all starting concentrations of 225 ng/ml). After 36 h at 37°C, Alamar Blue
REDOX indicator (Trek Diagnostic Systems, Medina, NY) was added to a
final concentration of 10% (v/v) to each well. Cells were allowed to grow
for 5–8 h more, after which plates were measured with a fluorometer.
Quantitation of mRNA expression
cDNA libraries from various tissue and cellular sources were prepared as
described previously (15) and used as templates for Taqman-PCR analyses.
cDNAs (50 ng/reaction) were analyzed for the expression of hTSLP,
hTSLPR, and hIL7Ra genes by the fluorogenic 59-nuclease PCR assay
(16), using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer,
Foster City, CA). Reactions were incubated for 2 min at 50°C, denatured
for 10 min at 95°C, and subjected to 40 two-step amplification cycles with
annealing/extension at 60°C for 1 min, followed by denaturation at 95°C
for 15 s. The amplicons used for hTSLP, hTSLPR, and IL-7Ra covered bp
246–315, 263–335, and 519–596, respectively (numbering starts at the
start codon), and were analyzed with 6-carboxyfluorescein (FAM)-labeled
probes. Values were expressed as femtograms per 50 ng total cDNA. Prim-
ers and probes for human chemokine and chemokine receptors were ob-
tained from Perkin-Elmer as predeveloped assay reagents. Chemokine and
chemokine receptor expression was adjusted for the amount of 18SrRNA
and compared with the control (calibrator) samples using the comparative
DD CT method (17). Samples were measured in duplicate. 18S rRNA levels
were determined under primer-limited conditions in multiplex reactions as
recommended using a Vic-labeled probe (Perkin-Elmer).
Cell isolation and culture
PBMC were purified from buffy coats of healthy volunteers (Stanford
Blood Bank, Palo Alto, CA) by centrifugation over Ficoll. Human mono-
cytes were isolated from PBMC by negative depletion using anti-CD2 (Leu
5A), anti-CD3 (Leu 4), anti-CD8 (Leu 2a), anti-CD19 (Leu 12), anti-CD20
(Leu 16), anti-CD56 (Leu 19; BD PharMingen, San Jose CA), anti-CD67
(IOM 67; Immunotech, Westbrook, ME), and anti-glycophorin A (10F7
MN; American Type Culture Collection, Manassas, VA) mAbs and sheep
anti-mouse IgG-coupled magnetic beads (Dynal, Oslo, Norway) as de-
scribed previously (18). Monocytes were cultured in RPMI and 10% FCS
at a density of 106 cells/ml in the presence or the absence of IL-7 (50
ng/ml) and/or hTSLP (50 ng/ml) for 24 h, and culture supernatants and
cells were harvested for quantitation of cytokine production or gene ex-
pression analyses. Human CD11c1 dendritic cells (DC) were isolated from
PBMC as previously described (19). Briefly, PBMC were incubated with
anti-CD3, anti-CD14, anti-CD19, and anti-CD56 mAbs and depleted from
lineage-positive cells using magnetic beads (Dynal), and CD11c1 lineage-
negative blood DC were subsequently isolated by cell sorting to reach a
purity of .99%. Freshly sorted cells were cultured in RPMI 1640 con-
taining 10% FCS at 5 3 104/100 ml in flat-bottom 96-well half-area culture
plates or at 1 3 105/200 ml in flat-bottom 96-well plates, with or without
TSLP (15 ng/ml).
TARC ELISA
The production of trymus and activation-regulated chemokine (TARC)/
CCL17 in culture supernatants was determined by chemokine-specific ELISA
using MAB364 as capture reagent and BAF364 as detection reagent (R&D
Systems, Minneapolis, MN). The sensitivity of the assay was 50 pg/ml.
DC viability and flow cytometric analysis
After 24 h of culture, DC were harvested and resuspended in an EDTA-
containing medium to dissociate the clusters. Viable DC were first counted
using trypan blue exclusion of dead cells. Remaining cells were stained
with a variety of mouse anti-human FITC-conjugated mAbs including anti-
HLA-DR (BD Biosciences, Mountain View, CA); anti-CD40, -CD80, and
-CD86 (all from PharMingen); or an Ig-G1 isotype control (BD Bio-
sciences) and were analyzed with a FACScan flow cytometer (BD Bio-
sciences). Dead cells were excluded based on side and forward scatter
characteristics.
T cell proliferation assay
Naive CD41/CD45CD45RA1 T cells were isolated from adult blood buffy
coats by negative depletion of cells expressing CD14, CD19, CD56, CD8,
CD45RO, HLA-DR, and glycophorin A using magnetic beads (Dynal).
More than 95% of the purified cells had the CD41CD45RA1 naive T cell
phenotype. CD11c1 DC were washed twice to remove any cytokine and
cocultured with 5 3 104 allogeneic naive CD41 T cells in round-bottom
96-well culture plates at increasing DC/T cell ratios. All cocultures were
conducted in triplicate. DC alone and T cells alone were used as controls.
After 5 days cells were pulsed with 1 mCi [3H]thymidine (Amersham,
Arlington Heights, IL) for 16 h before harvesting and counting of
radioactivity.
Stat3 and Stat5 activation assays
Stable Ba/F3 transfectant cells (;2.5 3 107 cells) were starved for 4–6 h
and then stimulated at 106 cells/ml for 15 min with either 10 ng/ml mIL-3
or 30 ng/ml hTSLP. After stimulation cells were harvested and incubated
for 15 min at 4°C in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 300
mM NaCl, 2 mM EDTA, 0.875% Brij 97, 0.125% Nonidet P-40, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 1 mM Na3VO4, and 1 mM
NaF. Cell lysates were clarified by centrifugation at 12,000 3 g for 15 min,
and supernatants were subjected to 8% SDS-PAGE. Proteins were elec-
trotransferred onto nylon membranes (Immobilon-P, Millipore, Bradford,
MA) and detected by Western blot analysis using rabbit Abs against anti-
phospho-Stat3 and anti-phospho-Stat5 (New England Biolabs, Beverly,
MA) or anti-Stat3 and anti-Stat5 (Santa Cruz Biotechnology, Santa Cruz,
CA), followed by mouse anti-rabbit Ig HRP. Immunoreactive bands were
visualized with ECL (SuperSignal West Dura Extended Duration Sub-
strate, Pierce, Rockford, IL) on ECL film (Eastman Kodak, Rochester,
NY). For reprobing blots were stripped with 200 mM glycine and 1% SDS,
pH 2.5, for 30 min at 65°C.
Results
Human TSLP was identified computationally
Genomic databases were searched with a computationally derived
sequence profile of the IL-7 helical cytokine family using methods
described by Oppmann et al. (20). This search identified an ex-
pressed sequence tag (GenBank accession no. AA889581) encod-
ing an almost full-length novel human cytokine. A search across a
panel of cDNA libraries of various tissues and cell lines identified
the lung fibroblast sarcoma cell line MRC5 as a source for a full-
length clone of this novel cytokine. The open reading frame (Fig.
1A) encodes a 159-residue polypeptide that includes a 28-amino
acid signal sequence. This novel human cytokine most likely rep-
resents the human orthologue of mTSLP (Fig. 1C), although the
low sequence identity between the two proteins (43%) is reminis-
cent of the great divergence between human and mouse IL-3 (21).
The N-terminal hTSLP residue was determined to be Y29, so the
mature sequence (residues 29–159) encodes a protein with calcu-
lated m.w. of 14.9 kDa with six cysteine residues and two N-
glycosylation sites. Human TSLP was expressed and purified from
adenovirus hTLSP-infected 293 cells and analyzed on SDS gels
(data not shown); the purified protein has a Mr of 23 kDa, indi-
cating that the mature protein is glycosylated. Quantitative PCR
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analysis of a large panel of human cDNAs from various libraries
and cultured cell lines showed that hTSLP expression of a 1.3-kb
message was restricted to a few lung libraries and several mono-
cyte cell samples (data not shown).
Identification of a receptor for hTSLP
Mouse TSLP binds to a specific receptor named mTSLPR (7). This
recently described molecule is most closely related to Rgc, the
shared receptor present in the signaling complexes for IL-2, IL-4,
IL-7, IL-9, IL-15, and possibly IL-21 (22). Both Rgc and mTSLPR
sequences were used in a focused search for a candidate hTSLPR
gene; consequently, a cDNA that encoded an orphan member of
the hemopoietin receptor family was identified from a proprietary
database (HGS, Rockville, MD). This cDNA, designated hTLSPR,
contains an open reading frame encoding a 371-aa protein with a
single transmembrane region (Fig. 1B). Human TSLPR displays
the closest identity to mTSLPR (39%) followed by Rgc (24%), and
most likely represents the human orthologue of mTSLPR (Fig.
1C). Intriguingly, an alternatively spliced, soluble, short form of
the mTSLPR has been described (10), suggesting that an analo-
gous human molecule could serve as a secreted inhibitor of
hTSLP.
Identification of a functional heteromeric human TSLP receptor
complex
The functional receptor complex for mTSLP consists of mTSLPR
and mIL-7Ra. To test the hypothesis that the functional receptor
for hTLSP consists of hTSLPR and hIL-7Ra, Ba/F3 cells were
FIGURE 1. Human TSLP and TLSPR sequence and evolution. A, Alignment of protein sequences for human and mouse TSLP (GenBank accession no.
AF232937). The four predicted a-helices of the canonical hemopoietic cytokine fold in human and mouse TSLP are labeled A, B, C, and D. Identical
residues are shaded black. B, The amino acid sequence of human TSLPR is shown in alignment with mTSLPR (GenBank accession no. AF201963).
Identical residues are shaded black. The signal peptide and transmembrane domains are shown. The characteristic class I cytokine receptor motifs WSXWS
and box 1 are boxed; the more typical WSXWS sequence is replaced by the sequence PSDWS in hTSLP and by PSEWT in mTSLP. C, Evolutionary
dendrogram of selected short chain hemopoietic cytokines (left panel) and their receptors (human and mouse orthologues; right panel). The receptor tree
is rooted by GHR (growth hormone receptor). Sequence data for human TSLP are available from GenBank under accession number AF338732. Sequence
data for human TSLPR are available from GenBank under accession number AF338733.
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infected with retroviral constructs encoding the receptors. While
parental Ba/F3 cells would only proliferate in response to IL-3,
those cells infected with either hTSLPR or hIL-7Ra alone showed
no proliferative response when either hTSLP or hIL-7 was added
(Fig. 2, A and B). However, Ba/F3 cells expressing both receptors
proliferated strongly in response to hTSLP, but not at all upon
addition of hIL-7 (Fig. 2C). The response was specific for hTSLP,
as mTSLP was not able to induce proliferation (Fig. 2C). This
finding establishes that the functional receptor for hTSLP consists
of two subunits, hTSLPR and hIL-7Ra; furthermore, we observed
no cross-reactivity between mTSLP and the hTSLP receptor com-
plex. The corresponding activation status of Stat5 and Stat3 was
also measured in the various Ba/F3 cell populations. Fig. 3 shows
that both Stat5 and Stat3 were phosphorylated upon addition of
hTSLP, but only when both hTSLPR and hIL-7Ra were present.
Coexpression of TSLPR and IL-7Ra in human DC and
monocytes
To identify possible target cells capable of responding to hTSLP
we have analyzed by quantitative PCR a large panel of human
cDNA libraries for the simultaneous expression of both TSLPR
and IL-7Ra mRNAs (Fig. 4). Several cell types expressed both
receptors. Th cell clones, in particular activated DC, and to a lesser
extent monocytes produced significant levels of both receptors,
suggesting that these cell types might respond to TSLP.
TSLP induces TARC on freshly isolated monocyte populations
and CD11c1 blood DC
The spectrum of biological activities induced by TSLP was inves-
tigated based on the overlapping expression patterns of TSLP re-
ceptor components. cDNA was prepared from human monocytes
cultured for 24 h in the presence of TSLP or IL-7, and the expres-
sion of 38 human chemokines and 20 human chemokine receptors
was analyzed by quantitative real-time PCR. Interestingly, TSLP
and IL-7 influenced the expression of distinct sets of chemokines
(Table I), but did not affect the expression of chemokine receptors.
TSLP enhanced the expression of TARC/CCL17, DC-CK1/pul-
monary and activation-regulated chemokine (PARC)/CCL18,
macrophage-derived chemokine (MDC)/CCL22, and MIP3b/
CL19. IL-7 also enhanced the expression of TARC/CCL17, MDC/
CCL22, and MIP3b/CCL19, but, in addition, enhanced the expres-
sion of IL-8/CXCL8, CTAPIII/CXCL7, ENA78/CXCL5, and
GROabg/CXCL123 and decreased the expression levels of IP-10/
CXCL10, I-TACK/CXCL11, SDF1/CXCL12, MCP2/CCL8, and
MCP4/CCL13 (Table I). The induction of TARC protein by TSLP
on monocyte and DC populations was confirmed by ELISA. The
level of TARC production by CD11c1 DC was at least 10-fold
higher than that by monocytes (Fig. 5).
FIGURE 2. TSLP signaling requires TSLPR and IL-7Ra. Ba/F3 cells
were infected with retroviruses encoding hTSLPR or hIL-7Ra or were
coinfected with hTSLPR and hIL-7Ra constructs. Proliferation of cells
upon stimulation with either IL-7 or TSLP was determined after addition of
Alamar Blue and was measured at 570–600 nm. Data represent one of
three experiments with similar results. The mean of triplicate determina-
tions is shown. The parental Ba/F3 cells proliferate only in response to
mIL-3 (10 ng/ml). A, Ba/F3 cells expressing IL-7Ra do not respond to IL-7
or TSLP. B, Ba/F3 cells expressing hTSLPR do not respond to IL-7 or
TSLP. C, Ba/F3 cells coexpressing hTSLPR and hIL-7Ra proliferate in the
presence of hTSLP, but not upon addition of hIL-7 or mTSLP. l, mIL-3;
F hTSLP; M mTSLP; E, hIL-7; , medium.
FIGURE 3. TSLP induces phosphorylation of Stat3 and Stat5. Ba/F3
cells expressing hIL-7Ra, hTSLPR, or both were stimulated (see Materials
and Methods) with control, mIL-3 (10 ng/ml), or hTSLP (20 ng/ml), and
phosphorylation was assessed by Western blot using anti-phospho-Stat5
Ab (A) and anti-phopho-Stat3 Ab (B). Blots were reprobed using anti-Stat5
(A) and Stat3 Abs (B). Phosphorylation of Stat5 and Stat3 by hTSLP was
only detected on cells expressing both receptors.
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TSLP activates CD11c1 DC
Freshly purified immature CD11c1 blood DC are known to spon-
taneously mature in culture (23). After 24 h in medium alone, we
observed loose and irregular clumps in the DC culture (Fig. 6A). In
the presence of TSLP this maturation process was dramatically
enhanced. DC in culture formed tight and round clumps with fine
dendrites visible at the periphery of each clump (Fig. 6B). The
TSLP-induced maturation was confirmed by analyzing the surface
phenotype of DC using flow cytometry. Whereas TSLP slightly
up-regulated the expression of HLA-DR and CD86, it strongly
induced the costimulatory molecules CD40 and CD80 (Fig. 6C).
This maturation process was accompanied by an increased viabil-
ity of the DC (data not shown). A titration of TSLP using log
dilutions of the cytokine showed that both the effect on survival
and the induction of costimulatory molecules on DC were maximal
at 15 ng/ml and above and were still significant at concentrations
as low as 15 pg/ml (data not shown).
We next analyzed the T cell stimulatory capacity of CD111 DC
cultured 24 h in medium alone or in the presence of TSLP. DCs
were cocultured with 5 3 104 naive CD41CD45RA1 allogeneic T
cells at increasing DC/T cell ratios. As assessed by [3H]thymidine
incorporation on day 5 of the coculture, DC cultured with TSLP
induced up to 10-fold stronger naive T cell proliferation compared
with DC cultured in medium (Fig. 6D).
Discussion
We describe a novel human hemopoietic cytokine and its func-
tional receptor complex. Comparison with the recently published
sequence of mouse TSLP (6) suggests that the cytokine reported
here is the human orthologue of mTSLP, although the degree of
identity between the two proteins is low (43%). Identification of
the functional hTSLP receptor complex lends further support for
the evolutionary correspondence between human and mouse
TSLP. As described here, the functional hTSLP receptor consists
FIGURE 4. Expression profiles of TSLPR and IL-7Ra. Expression of TSLPR and IL-7Ra was measured by quantitative PCR (see Materials and
Methods) on a panel of human (h) cDNA libraries made from various tissues and cell types. Cells were often left untreated or were treated with different
stimuli as indicated before RNA was isolated. Expression levels were normalized and expressed as femtograms per 50 ng total cDNA. Coexpression of
TSLPR and IL-7Ra was detected in DC, monocytes, and, to a lesser extent, T cells.
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of two subunits. The first, TSLPR, is a novel member of the he-
mopoietin receptor superfamily and is most closely related to the
recently described mTSLPR, although both proteins have diverged
substantially (39% identity). The low degree of human vs mouse
sequence identity between ligands thus is mirrored in the align-
ment of receptor chains, consistent with the idea that these inter-
acting molecules have coevolved (24). The closest relative of
TSLPR is Rgc, the shared receptor present in the signaling com-
plexes for IL-2, IL-4, IL-7, IL-9, and IL-15. This link suggests that
TSLPR is possibly a promiscuous receptor, although it cannot sub-
stitute in any of the signaling complexes that involve Rgc (data not
shown). The second subunit of the functional hTSLP receptor is
IL-7Ra, a chain that is also part of the functional IL-7R. Thus, the
functional receptors for human and mouse TSLP both require the
species-specific forms of TSLPR and IL-7Ra. We have not ob-
served cross-species activity of either human or mouse TSLP. In
contrast, both human and mouse IL-7 show cross-species
activities.
Investigation of the spectrum of biological actions induced by
hTSLP was guided by the common expression patterns of TSLP
receptor components. Both receptor subunits are primarily ex-
pressed by dendritic cells and to a lesser extent by monocytes, with
expression of IL-7Ra in general approximately 10-fold higher than
that of TSLPR. On freshly isolated human monocytes TSLP spe-
cifically induced the chemokines TARC, PARC, and MDC, which
are all notably ligands for CCR4, a chemokine receptor predom-
inantly found on Th2-type lymphocytes. Thus, TSLP can activate
monocytes to release chemokines that may attract effector cells
with a Th2 phenotype. TSLP-induced expression of TARC was
very strong in the CD11c1 subset of DCs. This subset, represent-
ing ,1% of mononuclear cells in the blood, normally differentiates
into mature DCs in response to inflammatory stimuli. The expres-
sion of TARC in these cells was accompanied by a dramatic en-
hancement of their maturation, as evidenced by the strong induc-
tion of the costimulatory molecules CD40 and CD80. These results
suggest that this DC subset stimulated with TSLP could be a potent
inducer of primary T cell-mediated immune responses. Indeed,
CD111 DCs cultured in the presence of TSLP were much more
potent in their capacity to elicit the proliferation of naive T cells
than DC cultured in medium.
Since both mouse and human TSLP share the IL-7R a-chain
with IL-7, some overlap in function between these two cytokines
can be expected. In mice IL-7 mediates T and B cell lymphopoi-
esis, and targeted deletion of IL-7 or its receptor subunits (IL-7Ra
or Rgc) leads to severe T and B lymphopenia (25–28). Both in
vitro and in vivo mTSLP has been reported to costimulate thymo-
cytes and mature T cells and to support the growth of pre-B cells,
although the precise definition of the in vivo importance of mTSLP
remains to be established (1, 3, 6). There is a prominent discrep-
ancy between the function of IL-7 in mice vs humans; in the latter,
IL-7 is critical for T lineage, but not B lineage, development, and
either Rgc or IL-7Ra deficiency results in the arrest of only T cell
development (T2B1 SCID) (29–32). This argues against a major
role of either hTSLP or IL-7 in human B cell development. Indeed,
preliminary evidence from our laboratory suggests that hTSLP
cannot support the growth of CD341 CD191 B cell precursors
from normal human bone marrow either alone or in combination
with IL-7. Some T cell clones, however, coexpress TSLPR and
IL-7Ra transcripts, suggesting that some T cells can respond to
hTSLP. This finding is presently under investigation.
It appears from the work described here that the biological ac-
tivity of TSLP, at least in humans, is not restricted to lymphoid
cells. In fact, based on the prominent expression of both TSLP
receptor subunits on cells of myeloid origin it is likely that TSLP
mainly functions on cells of the myeloid lineages. Activities of
mTSLP on these cells have not yet been reported, but the recent
Table I. Effects of TSLP and IL-7 on chemokine expressiona
Media TSLP IL-7
CCL1 40.0 1.0 1.4
CCL2 24.8 1.0 1.5
CCL3 31.5 0.7 2.0
CCL4 28.9 1.0 1.6
CCL5 30.4 1.1 0.6
CCL7 31.3 0.7 1.4
CCL8 30.2 0.8 0.2
CCL11 40.0 1.6 1.4
CCL13 37.3 1.6 0.1
CCL14 40.0 1.3 1.3
CCL15 40.0 1.1 1.3
CCL16 40.0 2.2 7.0
CCL17 39.8 195.4 20.1
CCL18 35.8 2.9 1.7
CCL19 36.7 8.5 8.3
CCL20 40.0 1.2 1.2
CCL21 40.0 1.0 1.0
CCL22 34.3 8.8 3.0
CCL24 29.3 2.0 1.2
CCL25 40.0 1.1 1.1
CCL26 38.9 1.1 2.5
CCL27 40.0 0.8 1.2
CCL28 40.0 1.0 1.0
CXCL1-3 28.7 1.0 4.4
CXCL4 27.9 1.2 1.9
CXCL5 28.7 1.1 8.0
CXCL6 40.0 1.5 1.3
CXCL7 28.7 1.1 2.0
CXCL8 27.3 1.4 8.5
CXCL9 34.9 0.6 0.7
CXCL10 29.7 0.6 0.1
CXCL11 32.9 0.7 0.0
CXCL12 33.1 0.6 0.2
CXCL13 35.4 0.2 0.8
CXCL14 39.7 1.0 1.0
XCL1 40.0 0.9 3.8
CX3CL1 40.0 1.4 1.3
a Human monocytes were cultured in the absence or presence of hTSLP (50 ng/
ml) or IL-7 (50 ng/ml) for 18 h, and expression of chemokine genes was determined
by quantitative PCR. Results are expressed as 1) CT values of nonactivated samples
and 2) fold difference relative to the calibrator sample (media). Boldface values in-
dicate significant changes.
FIGURE 5. Induction of TARC by TSLP. Human monocytes (A) or
CD11c1 DC (B) were cultured in the absence or the presence of TSLP (50
ng/ml) or IL-7 (50 ng/ml) for 24 h, and the production of TARC was
determined in the culture supernatant by ELISA.
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identification of a functional mTSLP-receptor complex invites a
similar analysis for the present work.
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